Summary:
In this open single-centre phase II study, MMF was added on day +10 after allogeneic transplantation to standard immunosuppressive prophylaxis consisting of cyclosporine and methotrexate to decrease the incidence of GvHD. In all, 30 patients aged 20–59 years with advanced haematological malignancies received an unmanipulated blood-stem-cell graft (median of 8.5 × 106 CD34+ and 349 × 106 CD3+ cells per bodyweight) from matched unrelated (n=26), or mismatched donors (n=4). Prior to transplantation, 13 patients underwent fractionated total body irradiation and cyclophosphamide, one patient additional etoposide. In all, 16 patients received reduced conditioning of fludarabin, busulfan, and antithymocyte globulin. All patients engrafted in a median of 12 days, and 19 developed acute GvHD⩾II, including two patients with GvHD III and three with GvHD IV. Subsequently, nine patients developed limited and two patients extensive chronic GvHD. With a median follow-up of 28 months, the overall survival is 53.3% and disease-free survival 50%, respectively. Only two deaths were due to GvHD IV. Out of 13 patients, 10 being CMV IgG positive became positive for pp65. In conclusion, this MMF schedule seems to be safe and feasible in the prophylaxis of severe acute GvHD for high-risk patients, restricted by an increased risk for reactivating CMV in seropositive patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fulton B, Markham A . Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278–298.
Sollinger HW . Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225–232.
Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation 1998; 66: 507–515.
Bullingham R, Monroe S, Nicholls A et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996; 36: 315–324.
Jenke A, Renner U, Richte M et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001; 15: 176–184.
Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999; 67: 499–504.
Basra N, Blau WI, Kiehl MG et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 2000; 14: 121–126.
Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for the prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Bornhäuser M, Kiehl M, Siegert W et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Hematol 2001; 115: 119–124.
Beelen DW, Elmaagacli A, Müller KD et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone in the development of acute graft-versus-host disease after marrow transplantation in patients with hematological malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267–3275.
Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation (first and second of two parts). N Engl J Med 1975; 292: 832–843, and 895–902.
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.
Basra N, Fauser AA . Safety profile of mycophenolate mofetil. Bone Marrow Transplant 2000; 25: 1362–1363.
Nademanee A, Schmidt GM, Parker P et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 1995; 86: 1228–1234.
Schetelig J, Kröger N, Held TK et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica 2002; 87: 299–305.
Niederwieser D, Maris M, Shizuru JA et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.
Blaha P, Bigenzahn S, Koporc Z et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 2003; 101: 2886–2893.
Kiehl MG, Shipkova M, Basra N et al. New strategies in GVHD prophylaxis. Bone Marrow Transplant 2000; 25 (S2): 16–19.
Basra N, Blau WI, Willenbacher W et al. New strategies in the treatment of graft-versus-host disease. Bone Marrow Transplant 2000; 25: 12–15.
Vogelsang GB, Arai S . Mycophenolate mofetil for the prevention of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001; 27: 1255–1262.
Feinstein LC, Sandmaier BM, Hegenbart U et al. Non-myeloablative allografting form human leukocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Hematol 2003; 120: 281–288.
Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.
Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695–1700.
Boeckh M, Leisenring W, Riddel SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407–414.
Junghanss C, Boeckh M, Catrer RA et al. Incidence and outcome of cytomegalovirus infection following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978–1985.
Hambach L, Stadler M, Dammann E et al. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29: 903–906.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kasper, C., Sayer, H., Mügge, L. et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 33, 65–69 (2004). https://doi.org/10.1038/sj.bmt.1704299
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704299
Keywords
This article is cited by
-
Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients
Bone Marrow Transplantation (2018)
-
Acute GVHD prophylaxis with standard-dose, micro-dose or no MTX after fludarabine/melphalan conditioning
Bone Marrow Transplantation (2014)
-
Distinct reconstitution of neutrophil functions after allogeneic peripheral blood stem cell transplantation
Journal of Cancer Research and Clinical Oncology (2007)
-
Chronic graft-versus-host disease: where is promise for the future?
Leukemia (2005)
-
Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model
Cancer Immunology, Immunotherapy (2005)